Small molecule · Inhibitor of NaV1.8 sodium channel (SCN10A) · developed by Latigo Biotherapeutics
LTG-321 is an orally bioavailable small molecule that inhibits the NaV1.8 sodium channel, being developed as a non-opioid analgesic.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07915947 | Phase 1 | PK Drug-drug Interaction Study | Not yet recruiting | LTGO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
PK Drug-drug Interaction Study
Updated Nov 15, 2026. Something wrong or missing? Report it on the LTGO page.
See LTGO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LTGO catalysts and pipeline →